Title |
Early Clinical Trials of New Anti Cancer Agents
|
Institution |
UNIVERSITY OF WISCONSIN MADISON, MADISON, WI
|
Principal Investigator |
WILDING, GEORGE
|
NCI Program Director |
S Percy Ivy
|
Cancer Activity |
Clinical Oncology
|
Division |
DCTD
|
Funded Amount |
$558,617
|
Project Dates |
02/27/1998 - 01/31/2009
|
Fiscal Year |
2007
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Chemotherapy (100.0%)
Gene Therapy (3.0%)
Gene Therapy Clinical Trials (3.0%)
Orphan Drug Research (100.0%)
Taxol (3.0%)
|
Lung (1.0%)
|
Research Type |
Localized Therapies - Clinical Applications
Systemic Therapies - Clinical Applications
|
Abstract |
DESCRIPTION (provided by applicant): Phase I clinical trials are the culmination of the costly and laborious preclinical screening process and are the foundation for studies of human antitumor activity. The University of Wisconsin has had continuous NCI funding for its phase I studies since 1979. This proposal details our extensive experience in conducting phase I trials and outlines our goals for continuation of such work as detailed in our specific aims:
Aim 1: Determination of Dose Limiting Toxicity and Maximum Tolerated Dose in Early Phase Trials
Aim 2: Definition of Pharmacokinetic and Pharmacodynamic Endpoints in Phase I Clinical Trials
Aim 3: Molecular Target Assessment in the Determination of Drug Mechanisms, Biologic Endpoints, and Response
Aim 4: New Designs and Paradigms for the Evaluation of Novel Agents |